Keywords: InterMune, Esbriet, IPF, Pulmonary hypertension Campaign

Longer-term safety profile of InterMune’s Esbriet in IPF demonstrated; Call for greater awareness of PF

Article | 26 September 2011

Print This

US biotech firm InterMune (Nasdaq: ITMN) has reported that new data at the European Respiratory Society (ERS) Annual Congress supporting ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in